Sharon L. Barrans

St James' University Hospital
Leeds, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 40 publications

Pathogenesis of diffuse large B cell lymphoma proteogenotypes.

Pathogenesis of diffuse large B cell lymphoma proteogenotypes.

Journal: Cancer cell
Published: December 03, 2024

Lymphoid blood cancers, incidence and survival 2005-2023: A report from the UK's Haematological Malignancy Research Network.

Lymphoid blood cancers, incidence and survival 2005-2023: A report from the UK's Haematological Malignancy Research Network.

Journal: Cancer epidemiology
Published: October 18, 2023

Non-IG::MYC in diffuse large B-cell lymphoma confers variable genomic configurations and MYC transactivation potential.

Non-IG::MYC in diffuse large B-cell lymphoma confers variable genomic configurations and MYC transactivation potential.

Journal: Leukemia
Published: September 26, 2023

Comparison of MHG and DZsig reveals shared biology and a core overlap group with inferior prognosis in DLBCL.

Comparison of MHG and DZsig reveals shared biology and a core overlap group with inferior prognosis in DLBCL.

Journal: Blood advances
Published: May 08, 2023

Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up.

Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 27, 2023

Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type diffuse large B-cell lymphoma.

Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type diffuse large B-cell lymphoma.

Journal: Blood advances
Published: March 18, 2022

DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes.

DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes.

Journal: Molecular cancer
Published: July 27, 2021

Molecular subclusters of follicular lymphoma: a report from the United Kingdom's Haematological Malignancy Research Network.

Molecular subclusters of follicular lymphoma: a report from the United Kingdom's Haematological Malignancy Research Network.

Journal: Blood advances
Published: May 17, 2021

Sequential inverse dysregulation of the RNA helicases DDX3X and DDX3Y facilitates MYC-driven lymphomagenesis.

Sequential inverse dysregulation of the RNA helicases DDX3X and DDX3Y facilitates MYC-driven lymphomagenesis.

Journal: Molecular cell
Published: March 29, 2021

Comparative analysis of gene expression platforms for cell-of-origin classification of diffuse large B-cell lymphoma shows high concordance.

Comparative analysis of gene expression platforms for cell-of-origin classification of diffuse large B-cell lymphoma shows high concordance.

Journal: British journal of haematology
Published: September 23, 2020

Application of the LymphGen classification tool to 928 clinically and genetically-characterised cases of diffuse large B cell lymphoma (DLBCL).

Application of the LymphGen classification tool to 928 clinically and genetically-characterised cases of diffuse large B cell lymphoma (DLBCL).

Journal: British journal of haematology
Published: August 10, 2020

Practical Application of Fluorescent In Situ Hybridization Techniques in Clinical Diagnostic Laboratories.

Practical Application of Fluorescent In Situ Hybridization Techniques in Clinical Diagnostic Laboratories.

Journal: Methods in molecular biology (Clifton, N.J.)
Published: May 13, 2020
Showing 1-12 of 40

Last Updated: 09/26/2026